AU2021351536A1 - Pharmaceutical formulations for treating diseases mediated by kdm1a - Google Patents
Pharmaceutical formulations for treating diseases mediated by kdm1a Download PDFInfo
- Publication number
- AU2021351536A1 AU2021351536A1 AU2021351536A AU2021351536A AU2021351536A1 AU 2021351536 A1 AU2021351536 A1 AU 2021351536A1 AU 2021351536 A AU2021351536 A AU 2021351536A AU 2021351536 A AU2021351536 A AU 2021351536A AU 2021351536 A1 AU2021351536 A1 AU 2021351536A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- compound
- amount
- capsules
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086353P | 2020-10-01 | 2020-10-01 | |
| US63/086,353 | 2020-10-01 | ||
| PCT/US2021/053141 WO2022072811A1 (en) | 2020-10-01 | 2021-10-01 | Pharmaceutical formulations for treating diseases mediated by kdm1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021351536A1 true AU2021351536A1 (en) | 2023-05-04 |
Family
ID=80951023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021351536A Pending AU2021351536A1 (en) | 2020-10-01 | 2021-10-01 | Pharmaceutical formulations for treating diseases mediated by kdm1a |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230293495A1 (https=) |
| EP (1) | EP4221704B1 (https=) |
| JP (1) | JP7848195B2 (https=) |
| KR (1) | KR20230079151A (https=) |
| CN (1) | CN116367831A (https=) |
| AU (1) | AU2021351536A1 (https=) |
| BR (1) | BR112023005987A2 (https=) |
| CA (1) | CA3193661A1 (https=) |
| MX (1) | MX2023003783A (https=) |
| WO (1) | WO2022072811A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962488A (en) * | 1998-04-08 | 1999-10-05 | Roberts Laboratories, Inc. | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
| US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
| TW201431552A (zh) | 2008-07-28 | 2014-08-16 | Takeda Pharmaceutical | 醫藥組成物 |
| US20100273825A1 (en) * | 2009-03-30 | 2010-10-28 | Astellas Pharma Inc. | Solid pharmaceutical composition containing solifenacin amorphous form |
| RU2627471C2 (ru) * | 2011-09-14 | 2017-08-08 | Селджин Корпорейшн | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
| WO2015170237A1 (en) * | 2014-05-05 | 2015-11-12 | Torrent Pharmaceuticals Limited | Stable solifenacin composition |
| CA2976350C (en) * | 2015-02-12 | 2023-09-19 | Hugh Young Rienhoff, Jr. | Kdm1a inhibitors for the treatment of disease |
| US20190070172A1 (en) * | 2015-11-05 | 2019-03-07 | Imago Biosciences, Inc. | Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms |
| TWI833686B (zh) | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| CN111194306B (zh) * | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| KR20220113753A (ko) * | 2019-12-09 | 2022-08-16 | 이마고 바이오사이언시즈 인코포레이티드 | 골수증식성 신생물의 치료를 위한 리신-특이적 히스톤 데메틸라제 억제제 |
-
2021
- 2021-10-01 CN CN202180068111.4A patent/CN116367831A/zh active Pending
- 2021-10-01 MX MX2023003783A patent/MX2023003783A/es unknown
- 2021-10-01 EP EP21876583.2A patent/EP4221704B1/en active Active
- 2021-10-01 CA CA3193661A patent/CA3193661A1/en active Pending
- 2021-10-01 BR BR112023005987A patent/BR112023005987A2/pt unknown
- 2021-10-01 KR KR1020237014383A patent/KR20230079151A/ko active Pending
- 2021-10-01 JP JP2023519794A patent/JP7848195B2/ja active Active
- 2021-10-01 AU AU2021351536A patent/AU2021351536A1/en active Pending
- 2021-10-01 WO PCT/US2021/053141 patent/WO2022072811A1/en not_active Ceased
-
2023
- 2023-03-23 US US18/188,578 patent/US20230293495A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116367831A (zh) | 2023-06-30 |
| WO2022072811A1 (en) | 2022-04-07 |
| EP4221704A1 (en) | 2023-08-09 |
| KR20230079151A (ko) | 2023-06-05 |
| MX2023003783A (es) | 2023-04-26 |
| EP4221704A4 (en) | 2024-11-06 |
| BR112023005987A2 (pt) | 2023-05-02 |
| EP4221704B1 (en) | 2025-09-24 |
| JP2023544327A (ja) | 2023-10-23 |
| US20230293495A1 (en) | 2023-09-21 |
| JP7848195B2 (ja) | 2026-04-20 |
| CA3193661A1 (en) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1441713B1 (en) | Modified release tamsulosin tablets | |
| RU2405540C1 (ru) | Таблетка с высоким содержанием лекарственного препарата | |
| US9962390B2 (en) | Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration | |
| US20230293495A1 (en) | Pharmaceutical formulations for treating diseases mediated by kdm1a | |
| US20040202716A1 (en) | Composition | |
| KR20090016611A (ko) | 메만틴의 약학 조성물 | |
| AU2018326596A1 (en) | High concentration dosage forms of pridopidine | |
| WO2019149917A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
| US20020123503A1 (en) | Cabergoline pharmaceutical compositions and methods of use thereof | |
| US9572806B2 (en) | Elution-stabilized preparation | |
| CN103717209B (zh) | 速释的含普拉格雷的稳定的口服药物组合物 | |
| CN108125918B (zh) | 依维莫司药物组合物 | |
| EP3052130B1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| KR20180036633A (ko) | 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법 | |
| US20240100088A1 (en) | Novel formulation for treating copper metabolism-associated diseases or disorders | |
| EA051661B1 (ru) | Фармацевтическая композиция для лечения заболеваний, опосредованных kdm1a | |
| EP4725474A1 (en) | A solid composition of eliglustat | |
| CN111643506B (zh) | 一种奥氮平氟西汀复方胶囊制剂及其制备方法 | |
| EP4736851A1 (en) | Levodopa-benserazide hydrochloride composition and preparation therefor | |
| WO2025265110A1 (en) | Oral pharmaceutical compositions comprising a naphthyridine compound | |
| JP2025524357A (ja) | 多数の顆粒 | |
| JP2022536955A (ja) | ジクロフェナミド組成物及び使用方法 | |
| WO2017114597A1 (en) | Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide | |
| CN108721241A (zh) | 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法 | |
| KR20200113116A (ko) | 데페라시록스를 포함하는 필름코팅정제 |